European Commission grants market authorisation for BioMarin’s Voxzogo
It is estimated that over 11,000 children across Europe, Middle East, and Africa are affected by achondroplasia and could be eligible for treatment with Voxzogo
It is estimated that over 11,000 children across Europe, Middle East, and Africa are affected by achondroplasia and could be eligible for treatment with Voxzogo
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
Achondroplasia is a genetic condition that causes severely short stature and disproportionate growth
Subscribe To Our Newsletter & Stay Updated